Amyloidosis - Epidemiology Forecast to 2029

Amyloidosis - Epidemiology Forecast to 2029

Summary

Amyloidosis is a rare disease characterized by extracellular and/or intracellular deposition of insoluble abnormal amyloid fibrils that alters the normal functions of the tissues in the organs (Holmes et al., 2019; Mayo Clinic, 2020). Amyloid is not normally found in the body, but it can be formed from several different types of protein and interferes with the organs’ normal function. Organs that may be affected by amyloidosis include the heart, kidneys, liver, spleen, nervous system, and digestive tract (Mayo Clinic, 2020).

The signs and symptoms of amyloidosis include dizziness, fluid retention, fatigue, fainting, an enlarged tongue, low blood pressure, and shortness of breath (Mayo Clinic, 2020; Stanford Health Care, 2020). There are different types of amyloidosis, such as immunoglobulin light chain (AL) amyloidosis (referred to as primary amyloidosis), hereditary transthyretin amyloidosis (ATTRh/m) (referred to as hereditary or familial amyloidosis), wild-type transthyretin amyloidosis (ATTR-wt), AA amyloidosis (referred to as secondary amyloidosis), and localized amyloidosis (National Organization for Rare Disorders, 2020; Stanford Health Care, 2020).

In 2019, the 7MM had 10,575 diagnosed incident cases of AL amyloidosis in men and women combined for all ages. The US accounted for the majority of these cases with 4,386 diagnosed incident cases, while the UK accounted for the fewest cases with 468 cases in 2019. The publisher's epidemiologists forecast an increase in the diagnosed incident cases of AL amyloidosis to 12,265 cases in 2029 in the 7MM at an Annual Growth Rate (AGR) of 1.60% during the forecast period. The publisher's epidemiologists forecast an increase in the diagnosed incident cases of AL amyloidosis to 16,876 cases in 2029 in the 7MM at an Annual Growth Rate (AGR) of 1.41% during the forecast period. In 2019, there were 75,033 diagnosed prevalent cases of AL amyloidosis in men and women combined, for all ages, in the 7MM. The US accounted for the majority of these cases with 23,350 cases, while Spain accounted for the fewest cases with 5,428 cases in 2019.

Scope

The Amyloidosis Report provides an overview of the risk factors and the global and historical trends for amyloidosis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). The report includes diagnosed incident cases and diagnosed prevalent cases of AL amyloidosis in these markets from 2019-2029.
The diagnosed incident cases and diagnosed prevalent cases of AL amyloidosis are further segmented by sex and age (all ages), and subtypes (AL cardiomyopathy, AL renal amyloidosis, and AL polyneuropathy).
The diagnosed prevalent cases of AL amyloidosis are also segmented by Mayo classification stages (stage I, II, III, and IV), and by previous diagnosis of multiple myeloma. The report also includes the diagnosed incident cases and diagnosed prevalent cases of ATTRh/m, ATTR-wt, and AA amyloidosis for all ages and both sexes combined. The diagnosed prevalent cases of ATTRh/m are further segmented by those who undergo liver transplantation.
The amyloidosis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to Buy

The Amyloidosis Epidemiology series will allow you to -

Develop business strategies by understanding the trends shaping and driving the global amyloidosis market.
Quantify patient populations in the global amyloidosis market to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the age groups that present the best opportunities for amyloidosis therapeutics in each of the markets covered.
Understand magnitude of amyloidosis by types and AL amyloidosis by subtypes.

Table of Contents

1.1 List of Tables
1.2 List of Figures

2 Amyloidosis: Executive Summary

2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology

3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of AL Amyloidosis
3.4.4 Diagnosed Prevalent Cases of AL Amyloidosis
3.4.5 Diagnosed Incident Cases and Prevalent Cases of AL Amyloidosis by Subtypes
3.4.6 Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
3.4.7 Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
3.4.8 Diagnosed Incident Cases of ATTR-h
3.4.9 Diagnosed Incident Cases of ATTR-wt and AA Amyloidosis
3.4.10 Diagnosed Prevalent Cases of ATTR-h, ATTR-wt, and AA Amyloidosis
3.4.11 Diagnosed Prevalent Cases of ATTR-h by Those Who Underwent Liver Transplantation
3.5 Epidemiological Forecast for Amyloidosis, 2019-2029
3.5.1 Diagnosed Incident Cases of AL Amyloidosis
3.5.2 Sex-Specific Diagnosed Incident Cases of AL Amyloidosis
3.5.3 Age-Specific Diagnosed Incident Cases of AL Amyloidosis
3.5.4 Diagnosed Incident Cases of AL Amyloidosis by Subtypes
3.5.5 Diagnosed Prevalent Cases of AL Amyloidosis
3.5.6 Sex-Specific Diagnosed Prevalent Cases of AL Amyloidosis
3.5.7 Age-Specific Diagnosed Prevalent Cases of AL Amyloidosis
3.5.8 Diagnosed Prevalent Cases of AL Amyloidosis by Types
3.5.9 Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
3.5.10 Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
3.5.11 Diagnosed Incident Cases of ATTR-h
3.5.12 Diagnosed Prevalent Cases of ATTR-h
3.5.13 Diagnosed Prevalent Cases of ATTR-h Who Underwent Liver Transplantation
3.5.14 Diagnosed Incident Cases of ATTR-wt
3.5.15 Diagnosed Prevalent Cases of ATTR-wt
3.5.16 Diagnosed Incident Cases of AA Amyloidosis
3.5.17 Diagnosed Prevalent Cases of AA Amyloidosis
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix

4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About the Publisher
4.4 Contact Us
4.5 Disclaimer

List of Tables

Table 1: Risk Factors and Comorbidities for Amyloidosis

List of Figures

Figure 1: 7MM, Diagnosed Incident Cases of AL Amyloidosis, Both Sexes, All Ages, 2019 and 2029
Figure 2: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, Both Sexes, All Ages, 2019 and 2029
Figure 3: 7MM, Diagnosed Prevalence of AL Amyloidosis, Men and Women, All Ages, 2019
Figure 4: 7MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of AL Amyloidosis
Figure 5: 7MM, Sources Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of AL Amyloidosis by Types
Figure 6: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis
Figure 7: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages
Figure 8: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma
Figure 9: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-h
Figure 10: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h, ATTR-wt, and AA Amyloidosis
Figure 11: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of ATTR-h Underwent Liver Transplantation
Figure 12: 7MM, Sources Used to Forecast the Diagnosed Incident Cases of ATTR-wt and AA Amyloidosis
Figure 13: 7MM, Diagnosed Incident Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 14: 7MM, Diagnosed Incident Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 15: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 16: 7MM, Diagnosed Incident Cases of AL Amyloidosis by Subtypes, All Ages, Both Sexes, N, 2019
Figure 17: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 18: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis, by Sex, All Ages, N, 2019
Figure 19: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Age, Both Sexes, N, 2019
Figure 20: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Types, All Ages, Both Sexes, N, 2019
Figure 21: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis by Mayo Classification Stages, All Ages, Both Sexes, N, 2019
Figure 22: 7MM, Diagnosed Prevalent Cases of AL Amyloidosis with Previous Diagnosis of Multiple Myeloma, All Ages, Both Sexes, N, 2019
Figure 23: 7MM, Diagnosed Incident Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 24: 7MM, Diagnosed Prevalent Cases of ATTR-h, Both Sexes, All Ages, N, 2019
Figure 25: 7MM, Diagnosed Prevalent Cases of ATTR-h Who Underwent Liver Transplantation, All Ages, Both Sexes, N, 2019
Figure 26: 7MM, Diagnosed Incident Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 27: 7MM, Diagnosed Prevalent Cases of ATTR-wt, Both Sexes, All Ages, N, 2019
Figure 28: 7MM, Diagnosed Incident Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019
Figure 29: 7MM, Diagnosed Prevalent Cases of AA Amyloidosis, Both Sexes, All Ages, N, 2019